Generated by AI
Corvus Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing immunology and oncology therapies for immune-mediated diseases and cancer. Corvus Pharmaceuticals Inc. centers its current work on immune modulator product candidates that target pathways involved in immune cell activation, signaling, and function. Its pipeline includes soquelitinib, a lead ITK inhibitor, along with other programs such as anti-CD73, A2AR, A2BR, and anti-CXCR2 approaches. The company’s research spans solid tumors, T-cell lymphomas, autoimmune disorders, allergic conditions, and infectious diseases. Corvus Pharmaceuticals Inc. is positioned in the biotechnology sector as a development-stage company advancing novel drug candidates through clinical evaluation, with a business model built around drug discovery, clinical development, and scientific partnerships.
Website901 Gateway Boulevard
South San Francisco, CA, 94080
United States
The latest articles about CRVS.
Corvus Pharma (NASDAQ:CRVS) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This transcript is brought to you by
Data supports ongoing registration Phase 3 trial in r/r PTCL, Phase 2 trial in atopic dermatitis and planned trials for hidradenitis suppurativa and...
Summary of Nov 16's posts. Generated by AI.
Summary of May 15's posts. Generated by AI.
Summary of May 18's posts. Generated by AI.
Investors talking about CRVS also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.